NO331103B1 - Polypeptid for induksjon av immunrespons mot Streptococcus Pneumoniae, polynukleotid og ekspresjonsvektor inneholdende dette samt vertscelle og fremgangsmate for produksjon av polypeptidet og vaksinesammensetning omfattende dette - Google Patents
Polypeptid for induksjon av immunrespons mot Streptococcus Pneumoniae, polynukleotid og ekspresjonsvektor inneholdende dette samt vertscelle og fremgangsmate for produksjon av polypeptidet og vaksinesammensetning omfattende detteInfo
- Publication number
- NO331103B1 NO331103B1 NO20026121A NO20026121A NO331103B1 NO 331103 B1 NO331103 B1 NO 331103B1 NO 20026121 A NO20026121 A NO 20026121A NO 20026121 A NO20026121 A NO 20026121A NO 331103 B1 NO331103 B1 NO 331103B1
- Authority
- NO
- Norway
- Prior art keywords
- polypeptide
- polynucleotide
- induction
- production
- host cell
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 2
- 102000040430 polynucleotide Human genes 0.000 title abstract 2
- 108091033319 polynucleotide Proteins 0.000 title abstract 2
- 239000002157 polynucleotide Substances 0.000 title abstract 2
- 229960005486 vaccine Drugs 0.000 title abstract 2
- 241000193998 Streptococcus pneumoniae Species 0.000 title 1
- 239000013604 expression vector Substances 0.000 title 1
- 230000028993 immune response Effects 0.000 title 1
- 230000006698 induction Effects 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 title 1
- 208000035143 Bacterial infection Diseases 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 206010061372 Streptococcal infection Diseases 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 208000022362 bacterial infectious disease Diseases 0.000 abstract 1
- 238000002405 diagnostic procedure Methods 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000010188 recombinant method Methods 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Pulmonology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21268300P | 2000-06-20 | 2000-06-20 | |
| PCT/CA2001/000908 WO2001098334A2 (en) | 2000-06-20 | 2001-06-19 | Streptococcus antigens |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20026121D0 NO20026121D0 (no) | 2002-12-19 |
| NO20026121L NO20026121L (no) | 2003-02-13 |
| NO331103B1 true NO331103B1 (no) | 2011-10-10 |
Family
ID=22792041
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20026121A NO331103B1 (no) | 2000-06-20 | 2002-12-19 | Polypeptid for induksjon av immunrespons mot Streptococcus Pneumoniae, polynukleotid og ekspresjonsvektor inneholdende dette samt vertscelle og fremgangsmate for produksjon av polypeptidet og vaksinesammensetning omfattende dette |
Country Status (18)
| Country | Link |
|---|---|
| EP (2) | EP2281891A3 (cg-RX-API-DMAC7.html) |
| JP (2) | JP5051959B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR100927767B1 (cg-RX-API-DMAC7.html) |
| CN (2) | CN101260149B (cg-RX-API-DMAC7.html) |
| AR (1) | AR033980A1 (cg-RX-API-DMAC7.html) |
| AU (2) | AU7038101A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2413450C (cg-RX-API-DMAC7.html) |
| CZ (1) | CZ2003154A3 (cg-RX-API-DMAC7.html) |
| EA (1) | EA006232B1 (cg-RX-API-DMAC7.html) |
| HU (1) | HU228706B1 (cg-RX-API-DMAC7.html) |
| IL (2) | IL153558A0 (cg-RX-API-DMAC7.html) |
| MX (1) | MXPA03000103A (cg-RX-API-DMAC7.html) |
| NO (1) | NO331103B1 (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ553554A (cg-RX-API-DMAC7.html) |
| PL (1) | PL214229B1 (cg-RX-API-DMAC7.html) |
| TR (1) | TR200704553T2 (cg-RX-API-DMAC7.html) |
| UY (1) | UY26783A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2001098334A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7128918B1 (en) | 1998-12-23 | 2006-10-31 | Id Biomedical Corporation | Streptococcus antigens |
| US7074415B2 (en) | 2000-06-20 | 2006-07-11 | Id Biomedical Corporation | Streptococcus antigens |
| AU2002351623A1 (en) * | 2001-12-20 | 2003-07-09 | Shire Biochem Inc. | Streptococcus antigens |
| TWI457133B (zh) | 2005-12-13 | 2014-10-21 | Glaxosmithkline Biolog Sa | 新穎組合物 |
| ES2707499T3 (es) | 2005-12-22 | 2019-04-03 | Glaxosmithkline Biologicals Sa | Vacuna de conjugado de polisacárido neumocócico |
| GB0607088D0 (en) | 2006-04-07 | 2006-05-17 | Glaxosmithkline Biolog Sa | Vaccine |
| PT2097102E (pt) | 2006-09-07 | 2012-08-03 | Glaxosmithkline Biolog Sa | Vacina de combinação tendo quantidades reduzidas de antigénio de poliovírus |
| MX2009011837A (es) | 2007-05-02 | 2010-04-22 | Glaxosmithkline Biolog Sa | Vacuna. |
| EA201391788A1 (ru) | 2007-06-26 | 2014-08-29 | Глаксосмитклайн Байолоджикалс С.А. | Вакцина, содержащая конъюгаты капсульных полисахаридов streptococcus pneumoniae |
| CA2694466A1 (en) * | 2007-07-23 | 2009-01-29 | Sanofi Pasteur Limited | Immunogenic polypeptides and monoclonal antibodies |
| HUE026586T2 (hu) | 2008-04-16 | 2016-06-28 | Glaxosmithkline Biologicals Sa | Vakcina |
| CN102223876A (zh) | 2008-09-26 | 2011-10-19 | 纳米生物公司 | 纳米乳剂治疗性组合物及其使用方法 |
| KR101450958B1 (ko) | 2009-04-30 | 2014-10-15 | 콜레이 파마시티컬 그룹, 인코포레이티드 | 폐렴구균 백신 및 그의 용도 |
| US8668911B2 (en) | 2009-05-14 | 2014-03-11 | The Regents Of The University Of Michigan | Streptococcus vaccine compositions and methods of using the same |
| US20120135037A1 (en) | 2009-06-01 | 2012-05-31 | Mizel Steven B | Flagellin fusion proteins and conjugates comprising pneumococcus antigens and methods of using the same |
| PT2473605T (pt) | 2009-09-03 | 2018-05-28 | Pfizer Vaccines Llc | Vacina pcsk9 |
| GB201003924D0 (en) | 2010-03-09 | 2010-04-21 | Glaxosmithkline Biolog Sa | Immunogenic composition |
| GB201003920D0 (en) * | 2010-03-09 | 2010-04-21 | Glaxosmithkline Biolog Sa | Method of treatment |
| KR101272351B1 (ko) | 2010-04-23 | 2013-06-07 | 이화여자대학교 산학협력단 | 새로운 카나마이신 화합물, 카나마이신 생산 스트렙토마이세스 속 미생물 및 카나마이신의 생산 방법 |
| US20140004142A1 (en) | 2011-03-02 | 2014-01-02 | Pfizer Inc. | Pcsk9 vaccine |
| CA2834834A1 (en) | 2011-05-17 | 2012-11-22 | Glaxosmithkline Biologicals S.A. | Vaccine against streptococcus pneumoniae |
| US11708411B2 (en) | 2013-12-20 | 2023-07-25 | Wake Forest University Health Sciences | Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines |
| HRP20211288T1 (hr) | 2014-01-21 | 2021-11-26 | Pfizer Inc. | Kapsularni polisaharidi bakterije streptococcus pneumoniae i njihovi konjugati |
| US11160855B2 (en) | 2014-01-21 | 2021-11-02 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| DK3096783T3 (da) | 2014-01-21 | 2021-08-02 | Pfizer | Streptococcus pneumoniae-kapselpolysaccharider og konjugater deraf |
| PE20161095A1 (es) | 2014-01-21 | 2016-10-26 | Pfizer | Composiciones inmunogenicas que comprenden antigenos de sacaridos capsulares conjugados y uso de los mismos |
| WO2015121783A1 (en) | 2014-02-14 | 2015-08-20 | Pfizer Inc. | Immunogenic glycoprotein conjugates |
| HRP20230416T1 (hr) | 2015-01-15 | 2023-07-07 | Pfizer Inc. | Imunogeni pripravci, namijenjeni upotrebi u cjepivima protiv pneumokoka |
| KR20250058066A (ko) | 2015-07-21 | 2025-04-29 | 화이자 인코포레이티드 | 접합된 캡슐형 사카라이드 항원을 포함하는 면역원성 조성물, 그를 포함하는 키트 및 그의 용도 |
| GB201518684D0 (en) | 2015-10-21 | 2015-12-02 | Glaxosmithkline Biolog Sa | Vaccine |
| WO2017085586A1 (en) | 2015-11-20 | 2017-05-26 | Pfizer Inc. | Immunogenic compositions for use in pneumococcal vaccines |
| MX392525B (es) | 2017-01-20 | 2025-03-12 | Pfizer | Composiciones inmunogenicas para su uso en vacunas neumococicas |
| US20200222550A1 (en) | 2017-01-31 | 2020-07-16 | Merck Sharp & Dohme Corp. | Methods for production of capsular polysaccharide protein conjugates from streptococcus pneumoniae serotype 19f |
| EP3576784B1 (en) | 2017-01-31 | 2025-09-24 | Merck Sharp & Dohme LLC | Methods for making polysaccharide-protein conjugates |
| EP4656650A2 (en) | 2017-02-24 | 2025-12-03 | Merck Sharp & Dohme LLC | Pneumococcal conjugate vaccine formulations |
| JP7438102B2 (ja) | 2017-09-07 | 2024-02-26 | メルク・シャープ・アンド・ドーム・エルエルシー | 肺炎球菌多糖体および免疫原性多糖体－キャリアタンパク質コンジュゲートでのその使用 |
| MX2020005779A (es) | 2017-12-06 | 2020-10-28 | Merck Sharp & Dohme | Composiciones que comprenden conjugados de polisacarido de streptococcus pneumoniae con proteina y metodos de uso de estos. |
| US11260119B2 (en) | 2018-08-24 | 2022-03-01 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
| WO2020121159A1 (en) | 2018-12-12 | 2020-06-18 | Pfizer Inc. | Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof |
| AU2019401535B2 (en) | 2018-12-19 | 2023-12-14 | Merck Sharp & Dohme Llc | Compositions comprising Streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof |
| JP7239509B6 (ja) | 2019-02-22 | 2023-03-28 | ファイザー・インク | 細菌多糖類を精製するための方法 |
| CA3136278A1 (en) | 2019-04-10 | 2020-10-15 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof |
| KR20220042378A (ko) | 2019-07-31 | 2022-04-05 | 사노피 파스퇴르 인코포레이티드 | 다가 폐렴구균 다당류-단백질 접합체 조성물 및 그 사용 방법 |
| KR20220092572A (ko) | 2019-11-01 | 2022-07-01 | 화이자 인코포레이티드 | 에스케리키아 콜라이 조성물 및 그 방법 |
| CN115362177A (zh) | 2020-02-21 | 2022-11-18 | 辉瑞公司 | 糖类的纯化 |
| EP4107170A2 (en) | 2020-02-23 | 2022-12-28 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
| JP2023546446A (ja) | 2020-10-22 | 2023-11-02 | ファイザー・インク | 細菌多糖を精製する方法 |
| US12138302B2 (en) | 2020-10-27 | 2024-11-12 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
| WO2022090893A2 (en) | 2020-10-27 | 2022-05-05 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
| MX2023005221A (es) | 2020-11-04 | 2023-05-16 | Pfizer | Composiciones inmunogenicas para uso en vacunas neumococicas. |
| US12357681B2 (en) | 2020-12-23 | 2025-07-15 | Pfizer Inc. | E. coli FimH mutants and uses thereof |
| TW202245835A (zh) | 2021-02-04 | 2022-12-01 | 美商默沙東有限責任公司 | 用於肺炎球菌結合物疫苗之奈米乳化液佐劑組合物 |
| EP4333879A1 (en) | 2021-05-03 | 2024-03-13 | Pfizer Inc. | Vaccination against bacterial and betacoronavirus infections |
| WO2022234416A1 (en) | 2021-05-03 | 2022-11-10 | Pfizer Inc. | Vaccination against pneumoccocal and covid-19 infections |
| BR112023023671A2 (pt) | 2021-05-28 | 2024-02-06 | Pfizer | Composições imunogênicas compreendendo antígenos de sacarídeo capsular conjugados e usos dos mesmos |
| EP4346893A2 (en) | 2021-05-28 | 2024-04-10 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| CN118510548A (zh) | 2022-01-13 | 2024-08-16 | 辉瑞公司 | 包含缀合的荚膜糖抗原的免疫原性组合物及其用途 |
| WO2023161817A1 (en) | 2022-02-25 | 2023-08-31 | Pfizer Inc. | Methods for incorporating azido groups in bacterial capsular polysaccharides |
| JP2025516536A (ja) | 2022-05-11 | 2025-05-30 | ファイザー・インク | 保存剤を用いたワクチン製剤を作製するためのプロセス |
| WO2024084397A1 (en) | 2022-10-19 | 2024-04-25 | Pfizer Inc. | Vaccination against pneumoccocal and covid-19 infections |
| WO2024110827A1 (en) | 2022-11-21 | 2024-05-30 | Pfizer Inc. | Methods for preparing conjugated capsular saccharide antigens and uses thereof |
| AU2023385908A1 (en) | 2022-11-22 | 2025-05-15 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| WO2024116096A1 (en) | 2022-12-01 | 2024-06-06 | Pfizer Inc. | Pneumococcal conjugate vaccine formulations |
| EP4661911A1 (en) | 2023-02-10 | 2025-12-17 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| WO2024201324A2 (en) | 2023-03-30 | 2024-10-03 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| CN121057590A (zh) | 2023-04-14 | 2025-12-02 | 辉瑞公司 | 包含缀合荚膜糖抗原的免疫原性组合物及其用途 |
| WO2024224266A1 (en) | 2023-04-24 | 2024-10-31 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| AU2024271872A1 (en) | 2023-05-18 | 2025-12-18 | Merck Sharp & Dohme Llc | Compounds and adjuvant formulations useful in pneumococcal vaccines |
| WO2024241172A2 (en) | 2023-05-19 | 2024-11-28 | Glaxosmithkline Biologicals Sa | Methods for eliciting an immune response to respiratory syncycial virus and streptococcus pneumoniae infection |
| WO2025057078A1 (en) | 2023-09-14 | 2025-03-20 | Pfizer Inc. | Adjuvanted immunogenic compositions comprising conjugated pneumococcal capsular saccharide antigens and uses thereof |
| WO2025106603A1 (en) | 2023-11-16 | 2025-05-22 | Merck Sharp & Dohme Llc | Peptide conjugate vaccine compositions and methods for the treatment of alzheimer's disease |
| WO2025133971A1 (en) | 2023-12-23 | 2025-06-26 | Pfizer Inc. | Improved methods for producing bacterial capsular saccharide glycoconjugates |
| WO2025186705A2 (en) | 2024-03-06 | 2025-09-12 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| WO2025191415A1 (en) | 2024-03-11 | 2025-09-18 | Pfizer Inc. | Immunogenic compositions comprising conjugated escherichia coli saccharides and uses thereof |
| WO2025219908A2 (en) | 2024-04-19 | 2025-10-23 | Pfizer Inc. | Media and fermentation methods for polysaccharide production in bacterial cell culture |
| WO2025219904A1 (en) | 2024-04-19 | 2025-10-23 | Pfizer Inc. | Improved methods for producing glycoconjugates by reductive amination in aprotic solvent |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4425437A (en) | 1979-11-05 | 1984-01-10 | Genentech, Inc. | Microbial polypeptide expression vehicle |
| US4431739A (en) | 1979-11-05 | 1984-02-14 | Genentech, Inc. | Transformant bacterial culture capable of expressing heterologous protein |
| US4338397A (en) | 1980-04-11 | 1982-07-06 | President And Fellows Of Harvard College | Mature protein synthesis |
| US5866135A (en) * | 1994-04-21 | 1999-02-02 | North American Vaccine, Inc. | Group A streptococcal polysaccharide immunogenic compositions and methods |
| EP0831894A1 (en) * | 1995-06-07 | 1998-04-01 | Alberta Research Council | Immunogenic and immunostimulatory oligosaccharide compositions and methods of making and using them |
| DE69739981D1 (de) * | 1996-10-31 | 2010-10-14 | Human Genome Sciences Inc | Streptococcus pneumoniae-Antigene und Impfstoffe |
| CN1291233A (zh) * | 1997-09-24 | 2001-04-11 | 美国明尼苏达州大学 | 来自肺炎链球菌之人类补体c3降解蛋白酶 |
| WO2000006737A2 (en) * | 1998-07-27 | 2000-02-10 | Microbial Technics Limited | Streptococcus pneumoniae proteins and nucleic acid molecules |
| WO2000010599A2 (en) * | 1998-08-19 | 2000-03-02 | North American Vaccine, Inc. | IMMUNOGENIC β-PROPIONAMIDO-LINKED POLYSACCHARIDE PROTEIN CONJUGATE USEFUL AS A VACCINE PRODUCED USING AN N-ACRYLOYLATED POLYSACCHARIDE |
| JP2002526082A (ja) * | 1998-09-24 | 2002-08-20 | リージェンツ オブ ザ ユニバーシティ オブ ミネソタ | ストレプトコッカス・ニューモニア由来のヒト補体ｃ３分解ポリペプチド |
| DE69940439D1 (de) * | 1998-12-21 | 2009-04-02 | Medimmune Inc | Streptococcus pneumoniae proteine und immunogene fragmente für impstoffe |
| NZ512574A (en) * | 1998-12-23 | 2004-03-26 | Iaf Biochem Int | Novel streptococcus antigens useful as vaccines |
-
2001
- 2001-06-19 EP EP10179497A patent/EP2281891A3/en not_active Withdrawn
- 2001-06-19 JP JP2002504289A patent/JP5051959B2/ja not_active Expired - Fee Related
- 2001-06-19 MX MXPA03000103A patent/MXPA03000103A/es active IP Right Grant
- 2001-06-19 KR KR1020027017453A patent/KR100927767B1/ko not_active Expired - Fee Related
- 2001-06-19 AU AU7038101A patent/AU7038101A/xx not_active Withdrawn
- 2001-06-19 NZ NZ553554A patent/NZ553554A/en not_active IP Right Cessation
- 2001-06-19 CN CN200710181645.XA patent/CN101260149B/zh not_active Expired - Fee Related
- 2001-06-19 HU HU0301656A patent/HU228706B1/hu not_active IP Right Cessation
- 2001-06-19 CA CA2413450A patent/CA2413450C/en not_active Expired - Fee Related
- 2001-06-19 TR TR2007/04553T patent/TR200704553T2/xx unknown
- 2001-06-19 PL PL360413A patent/PL214229B1/pl unknown
- 2001-06-19 EA EA200201280A patent/EA006232B1/ru not_active IP Right Cessation
- 2001-06-19 CZ CZ2003154A patent/CZ2003154A3/cs unknown
- 2001-06-19 WO PCT/CA2001/000908 patent/WO2001098334A2/en not_active Ceased
- 2001-06-19 IL IL15355801A patent/IL153558A0/xx unknown
- 2001-06-19 AU AU2001270381A patent/AU2001270381B2/en not_active Ceased
- 2001-06-19 EP EP01949136A patent/EP1303612A2/en not_active Withdrawn
- 2001-06-19 CN CN01814388A patent/CN1449446A/zh active Pending
- 2001-06-20 UY UY26783A patent/UY26783A1/es not_active Application Discontinuation
- 2001-06-20 AR ARP010102945A patent/AR033980A1/es not_active Application Discontinuation
-
2002
- 2002-12-19 IL IL153558A patent/IL153558A/en not_active IP Right Cessation
- 2002-12-19 NO NO20026121A patent/NO331103B1/no not_active IP Right Cessation
-
2012
- 2012-05-23 JP JP2012117846A patent/JP5889103B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO331103B1 (no) | Polypeptid for induksjon av immunrespons mot Streptococcus Pneumoniae, polynukleotid og ekspresjonsvektor inneholdende dette samt vertscelle og fremgangsmate for produksjon av polypeptidet og vaksinesammensetning omfattende dette | |
| AR029322A1 (es) | Un polinucleotido de estreptococo aislado que codifica un polipeptido capaz de generar anticuerpos que tienen especificidad de union para un segundo polipeptido de secuencias reveladas, los polipeptidos mencionados y un proceso para su fabricacion, un polipeptido quimerico, compuesto por dichos segu | |
| Jenkinson et al. | Structure, function and immunogenicity of streptococcal antigen I/II polypeptides | |
| NO20004161L (no) | Gruppe B streptokoccus antigener | |
| BR0208944A (pt) | quadros de leitura aberta de streptococus pneumoniae codificando os antìgenos de polipeptìdeos e seus usos | |
| ATE479756T1 (de) | Streptococcus pneumoniae-antigene und impfstoffe | |
| MXPA03009294A (es) | Proteinas de superficie de streptococcus pyogenes. | |
| DE69735715D1 (de) | Cholin-bindendes Protein, welches als gegen Pneumokokken gerichtetes Vakzin verwendet wird | |
| ATE198051T1 (de) | Pneumokokken-polysaccharid-rekombinante- pneumolysin-konjugate als impfstoffe für die immunisierung gegen pneumokokken-infektionen | |
| WO2001031019A3 (en) | Neisserial antigenic peptides | |
| Basset et al. | Toll-like receptor (TLR) 2 mediates inflammatory responses to oligomerized RrgA pneumococcal pilus type 1 protein | |
| Choi et al. | Analysis of Streptococcus pneumoniae secreted antigens by immuno-proteomic approach | |
| DK2054431T3 (da) | Konformere af bakterielle adhæsiner | |
| De et al. | Purification and characterization of Streptococcus pneumoniae palmitoylated pneumococcal surface adhesin A expressed in Escherichia coli | |
| WO2003065973A8 (en) | Multivalent streptococcal vaccine compositions and methods for use | |
| NO20025146L (no) | Isolering og karakterisering av csa-operonet (ETEC-CS4 pili) og fremgangsmåter for anvendelse derav | |
| WO2004020609A3 (en) | Streptococcus pneumoniae antigens for diagnosis, treatment and prevention of active infection | |
| BR9908476A (pt) | Peptìdeo, composição terapêutica, e, processo para conferir imunidade protetora a um paciente, contra a infecção de s. pneumoniae | |
| EP1219635A3 (en) | Chlamydia pneumoniae antigenes | |
| Wästfelt et al. | The Rib and α Proteins Define a Family of Group B Streptococcal Surface Proteins that Confer Protective Immunity | |
| DE60031106D1 (de) | Fluordesoxyuridin-resistente streptococcus gordonii stämme | |
| Ge | Identification of the surface-associated proteins and functions of enolase of Streptococcus mutans | |
| AU2002210301A1 (en) | Bvh-a2 and bvh-a3 antigens of group b streptococcus | |
| BR0111886A (pt) | Antìgeno para estreptococos | |
| EP1950302A3 (en) | Streptococcus antigens |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |